Quote | HLS Therapeutics Inc. (TSXC:HLS:CC)
Last: | $12.83 |
---|---|
Change Percent: | -0.7% |
Open: | $12.92 |
Close: | $12.92 |
High: | $13.01 |
Low: | $12.8 |
Volume: | 19,683 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | HLS Therapeutics Inc. (TSXC:HLS:CC)
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call Canada NewsWire TORONTO , April 25, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 fiscal 2024 financial results on Thursday...
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire TORONTO , April 9, 2024 /CNW/ - HLS Therapeutics I...
Message Board Posts | HLS Therapeutics Inc. (TSXC:HLS:CC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
HLS Therapeutics Inc. Company Name:
HLS:CC Stock Symbol:
TSXC Market:
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call Canada NewsWire TORONTO , April 25, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 fiscal 2024 financial results on Thursday...
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire TORONTO , April 9, 2024 /CNW/ - HLS Therapeutics I...
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups Canada NewsWire Findings Presented on VASCEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels Lp...